N@N

IDIX, HLCS, HEB, GTXI, GNVC, GNMSF, Biomed - Genetics Stocks 24.73% undervalued

^{Published on 2011-01-26 12:42:14 - WOPRAI}
 

January 26, 2011 / M2 PRESSWIRE / BUYINS.NET / http://www.squeezetrigger.com is monitoring the Biomed - Genetics sector and these stocks are the most undervalued as of today. IDENIX PHARMACEUTICALS INC (NASDAQ:IDIX), HELICOS BIOSCIENCES CORP (OTC:HLCS), HEMISPHERX BIOPHARMA INC (AMEX:HEB), GTX INC (NASDAQ:GTXI), GENVEC INC (NASDAQ:GNVC), GENMAB A/S (OTC:GNMSF) are all expected to go Up as they are undervalued according to industry standard valuation metrics. The valuation model employs a three-factor approach to stock valuation using fundamental variables--the company's trailing 12-month Earnings-Per-Share (EPS), the analyst consensus estimate of the company's forecasted 12-month EPS, and the 30-year Treasury yield--to create a highly accurate reflection of a company's fair value.

The chart below displays the projected Fair Value and Valuation discount/premium of the most undervalued stocks in the highlighted industry group:

     Symbol     Company Name                        Last Close     Fair Value     Valuation                   Industry               
     IDIX       IDENIX PHARMACEUTICALS INC          4.64           6.16           24.73% undervalued          Biomed - Genetics      
     HLCS       HELICOS BIOSCIENCES CORP            0.16           1.28           87.50% undervalued          Biomed - Genetics      
     HEB        HEMISPHERX BIOPHARMA INC            0.5005         1.07           53.17% undervalued          Biomed - Genetics      
     GTXI       GTX INC                             2.94           11.76          75.00% undervalued          Biomed - Genetics      
     GNVC       GENVEC INC                          0.61           1.46           58.19% undervalued          Biomed - Genetics      
     GNMSF      GENMAB A/S                          11.35          22.94          50.53% undervalued          Biomed - Genetics      

Here are some of the variables that are utilized when calculating the Fair Market Valuation of a stock: Long-run EPS growth rate, Duration of Business-growth-cycle, Volatility of EPS growth rate, Systematic or beta risk of the firm, Correlation between the firm's EPS and the interest rate environment, EPS growth volatility, Dividend payout ratio, Buffer earnings, Interest rate related criteria: Interest rate (30 year yield) long-run level, Duration of interest rate cycle, Interest rate volatility. The Fair Market Valuation uses 12-month historic and forecasted EPS values and the current 30-year treasury yield as primary determinants. When calculating risk/return values such as the Sharpe ratio, the historic periods used are five years.

Some expected results of the Valuation Model are: the valuation of a stock increases in a declining interest rate environment. Increasing current and/or projected EPS will produce a higher Valuation. While long-term EPS growth would produce a corresponding long-term Valuation increase, concomitant long-term interest rate increases would offset EPS growth and depress the Valuation. The shorter a company's own business cycle, the higher its stock Valuation will be.

IDENIX PHARMACEUTICALS INC (NASDAQ:IDIX) - Idenix Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of drugs for the treatment of human viral and other infectious diseases in the United States and Europe. The company primarily focuses its research and development on the treatment for hepatitis C virus. The company develops nucleoside/nucleotide polymerase inhibitors, including IDX184, a liver-targeted nucleotide prodrug candidate, which is in phase IIa clinical trial; and IDX102 that completed late-stage preclinical development. It also develops IDX375, a novel palm-binding polymerase inhibitor that is in phase I program; IDX320, a protease inhibitor candidate, which is in phase I healthy volunteer clinical study; and NS5A inhibitors. In addition, the company licensed its telbivudine (Tyzeka/Sebivo), a drug for the treatment of hepatitis B virus, to Novartis Pharma AG; and GSK2248761, a drug candidate from the class of compounds known as non-nucleoside reverse transcriptase inhibitors (NNRTIs), for the treatment of human immunodeficiency virus type 1 and acquired immune deficiency syndrome to GlaxoSmithKline. The company was founded in 1998 and is headquartered in Cambridge, Massachusetts.

HELICOS BIOSCIENCES CORP (OTC:HLCS) - Helicos BioSciences Corporation, a life sciences company, focuses on the genetic analysis technologies for the research, drug discovery, and clinical diagnostics markets primarily in the United States. Its proprietary True Single Molecule Sequencing technology enables the analysis of genetic material by directly sequencing single molecules of DNA or single DNA copies of RNA. The companys Helicos genetic analysis platform consists of HeliScope single molecule sequencer; HeliScope analysis engine, an image analysis computer tower; associated reagents, which are chemicals used in the sequencing process; and disposable supplies. Its Helicos genetic analysis system is used for various applications in the areas of studying the human genome, disease association studies, molecular diagnostics, cancer research, pharmaceutical research and development, infectious diseases, autoimmune conditions, and agricultural research. The company was formerly known as Newco LS6, Inc. and changed its name to Helicos BioSciences Corporation in November 2003. Helicos BioSciences Corporation was founded in 2003 and is headquartered in Cambridge, Massachusetts.

HEMISPHERX BIOPHARMA INC (AMEX:HEB) - Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The companys products include Ampligen, an experimental drug that is under clinical development for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome, Hepatitis B, human immunodeficiency virus, renal cell carcinoma, and malignant melanoma; and Alferon N Injection for the treatment of genital warts. Its products also comprise Alferon LDO, a low-dose, oral liquid formulation of natural alpha interferon for influenza and viral diseases, which is in the early stage of development; and Oragens for the treatment of chronic viral and immunological disorders. The company has a strategic alliance with Accredo to develop certain marketing and distribution capacities for Ampligen in the United States. Hemispherx Biopharma, Inc. was founded in 1990 and is headquartered in Philadelphia, Pennsylvania.

GTX INC (NASDAQ:GTXI) - GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules to treat cancer, osteoporosis and bone loss, muscle loss, and other serious medical conditions. The company markets FARESTON (toremifene citrate) 60 mg tablets for the treatment of metastatic breast cancer in postmenopausal women through wholesale drug distributors in the United States. It is developing Toremifene citrate 80 mg, which completed pivotal Phase III clinical trial to reduce fractures and treat other estrogen deficiency side effects of androgen deprivation therapy in men with prostate cancer; and Toremifene 20 mg that is in pivotal Phase III clinical trial for the prevention of prostate cancer in high risk men with precancerous prostate lesions called high grade prostatic intraepithelial neoplasia. The company is also developing selective androgen receptor modulators comprising Ostarine, which completed Phase II clinical trials for the treatment of cancer cachexia and chronic sarcopenia; and GTx-758, an oral luteinizing hormone that completed two Phase I clinical trials for the treatment of advanced prostate cancer. It has a partnership agreement with Ipsen S.A. for the development and commercialization of toremifene 80 mg for the reduction of fractures in men with advanced prostate cancer on androgen deprivation therapy and toremifene 20 mg for the prevention of prostate cancer in patients with high grade prostatic intraepithelial neoplasia lesions. GTx, Inc. was founded in 1997 and is headquartered Memphis, Tennessee.

GENVEC INC (NASDAQ:GNVC) - GenVec, Inc., a clinical stage biopharmaceutical company, develops gene-based therapeutic drugs and vaccines in the United States. Its lead therapeutic product candidate, TNFerade biologic, is under Phase III clinical trial for the treatment of inoperable, locally advanced pancreatic cancer. The company is also evaluating TNFerade biologic for the treatment of various cancers, including esophageal cancer, head and neck cancer, rectal cancer, and soft tissue sarcomas. In addition, its hearing and balance disorders program investigates delivery of the atonal gene in the inner ear. Further, GenVec uses its proprietary adenovector technology to develop vaccines for infectious diseases, including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus, and herpes simplex virus type 2. The company has a research collaboration and licensing agreement with Novartis Institutes for BioMedical Research, Inc. to discover and develop treatments for hearing loss and balance disorders. It also has strategic alliances and research contracts with the U.S. department of homeland security, the U.S. department of agriculture, PATHS malaria vaccine initiative, the U.S. Naval Medical Research Center, and the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. The company was founded in 1992 and is based in Gaithersburg, Maryland.

GENMAB A/S (OTC:GNMSF) - Genmab A/S, a biotechnology company, engages in the development of human antibody therapeutics for the potential treatment of cancer. The companys product pipeline includes Ofatumumab, a human monoclonal antibody for the treatment of in development for Chronic lymphocytic leukemia, non-Hodgkins lymphoma, diffuse large B-cell lymphoma, Waldenstroms macroglobulinemia, rheumatoid arthritis, and relapsing remitting multiple sclerosis; Zalutumumab, which is in Phase III clinical trials and targets the epidermal growth factor receptor; and Daratumumab, a human antibody to target the CD38 molecule expressed on the surface of multiple myeloma tumor cells. Its other clinical programs comprise RG4930 that is in Phase II development for asthma targeting OX40L; and RG1512 targeting P-selectin, which is in Phase I development stage for treatment of peripheral vascular diseases. In addition, the companys pre-clinical products comprise HuMax-CD32b, HuMax-TF, HuMax-VEGF, HuMax-Her2, and HuMax-Wnt for the treatment of cancer. It has collaboration agreements with Glaxo-SmithKline to co-develop and commercialize ofatumumab; and Roche to conduct clinical studies with RG4930 and RG1512 antibodies. The company was founded in 1999 and is based in Copenhagen, Denmark.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net